C-peptide and 24-hour urinary c-peptide as markers to help classify types of childhood diabetes

Hormone Research in Paediatrics

Volumn 84, Issue 1, 2015, Pages 62-64

  Levitt Katz, Lorraine E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; BIOLOGICAL MARKER;

ANTIBODY TITER; AUTOIMMUNITY; CHILDHOOD DISEASE; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE MARKER; FAMILY HISTORY; GENETIC RISK; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; KETOACIDOSIS; NOTE; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; ADOLESCENT; CHILD; CLASSIFICATION; FEMALE; MALE; PRESCHOOL CHILD; URINE;

ADOLESCENT; BIOMARKERS; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; FEMALE; HUMANS; MALE;

EID: 84939563501     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000430094     Document Type: Note

References (31)

1. LaPorte RE, Tajima N, Akerblom HK, et al: Geographic differences in the risk of insulindependent diabetes mellitus: the importance of registries. Diabetes Care 1985; 8(Suppl 1):101-107.
2. Dabelea D, Mayer-Davisa EJ, Saydah S, et al: Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311: 1778-1786.
3. Umpierrez GE, Casals MMC, Gebhart SSP, Mixon PS, Clark WS, Phillips LS: Diabetic ketoacidosis in obese African-Americans. Diabetes 1995; 44: 790-795.
4. Winter WE, Maclaren NK, Riley WJ, Clarke DW, Kappy MS, Spillar RP. Maturity-onset diabetes of youth in black Americans. N Engl J Med. 1987; 316;285-291
5. Neu A, Feldhahn L, Ehehalt S, Hub R, Ranke MB: Type 2 Diabetes mellitus in children and adolescents is still a rare disease in Germany: a population-based assessment of the prevalence of type 2 diabetes and MODY in patients aged 0-20 years. Pediatric Diabetes 2009: 10: 468-473.
6. Ledermann HM: Is maturity onset diabetes at young age (MODY) more common in Europe than previously assumed? Lancet 1995; 345: 648.
7. Fajans SS, Bell GI, Polonsky KS: Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345: 971-980.
8. Lipton RB, Drum M, Li S, Choi H: Social environment and year of birth influence of type 1 diabetes risk for African-American and Latino children. Diabetes Care 1999; 22: 78-85.
9. Lipman TH: The epidemiology of type 1 diabetes in children 0-14 years of age in Philadelphia. Diabetes Care 1993; 16: 922-925.
10. Lipman TM, Jawad A, Murph KM, Tuttle A, Thompson RL, Ratcliffe SJ, Katz L: Incidence of type 1 diabetes in Philadelphia is higher in black than white children from 1995 to 1999: epidemic or misclassification? Diabetes Care 2006; 29: 2391-2395.
11. Amiel SA, Shermin RS, Simonson DC, lauritano AA, Tamborlane WV: Impaired insulin action in puberty: a contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986; 315: 215-219.
12. Arslanian SA, Kalhan SC: Correlations between fatty acid and glucose metabolism: potential explanation of insulin resistance at puberty. Diabetes 1994; 43: 908-914.
13. Writing Group for the SEARCH for Diabetes in Youth Study Group: Incidence of diabetes in youth in the United States. JAMA 2007; 297: 2716-2724.
14. Pihoker C, Gilliam LK, Ellard S, et al: Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab 2013; 98: 4055-4062.
15. Libman UM, Pietropaolo M, Trucco M, Dorman JS, LaPorte RE, Becker DJ: Islet cell autoimmunity in white and black children and adolescents with T1DM. Diabetes Care 1998; 21: 1824-1827.
16. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazo GF, Holman R: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Propective Diabetes Study Group. Lancet 1997; 350: 1288-1293.
17. Brooks-Worrell, BB, Narla R, Palmer J: Islet autoimmunity in phenotypic type 2 diabetes patients. Diabetes Obes Metab 2013; 15(Suppl 3):137-140.
18. Niskanen L, Karjalainen J, Sarlund H, et al: Five-year follow-up of islet-cell antibodies in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1991; 34: 401-408.
19. Tuomi T, Carlsson A, Li H, et al: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 1999; 48: 150-157.
20. Klingensmith GJ, Pyle L, Arslanian S, et al: The presence of GAD and IA-2 Antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care 2010; 33: 1970-1975.
21. Schober E, Rami B, Grabert M, et al: Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicenter database. Diabet Med 2009; 26: 466-473.
22. Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH: Fasting C-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatr Diabetes 2007: 8:53-59.
23. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K; International Society for Pediatric and Adolescent Diabetes: ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 2006; 7: 352-360.
24. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H; Type 1 Diabetes Trial Net Research Group, European C-Peptide Trial Study Group: Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008; 31: 1966-1971.
25. Wang L, Lovejoy NF, Faustman DL: Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012; 35: 465-470.
26. Besser RE, Shields BM, Casas R, Hattersley AT, Ludvigsson J: Lessons from the mixedmeal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 2013; 36: 195-201.
27. Clarson C, Daneman D, Drash, et al: Residual beta cell function in children with T1DM: Reproducibility of testing and factors influenicing insulin secretory reserve. Diabetes Care 1987; 10: 33-38.
28. Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT: Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011; 34: 607-609.
29. Y?lmaz Agladioglu S, Sagsak E, Aycan Z: Urinary C-peptide/creatinine ratio can distinguish maturity-onset diabetes of the young from type 1 diabetes in children and adolescents: a single-center experience. Horm Res Paediatr 2015, Epub ahead of print.
30. Besser RE, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S, Hattersley AT: Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-{alpha}/hepatocyte nuclear factor 4-{alpha} maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011; 34: 286-291.
31. Besser RE, Shields BM, Hammersley SE, Colclough K, McDonald TJ, Gray Z, et al: Home urine C-peptide creatinine ratio (UCPCR) testing can identify type 2 and MODY in pediatric diabetes. Pediatr Diabetes 2013; 14: 181-188.